These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12091008)

  • 21. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
    Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B
    Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
    Oparil S
    Curr Hypertens Rep; 2002 Jun; 4(3):219-20. PubMed ID: 12003704
    [No Abstract]   [Full Text] [Related]  

  • 23. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 24. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 27. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
    Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
    Ciulla MM; Paliotti R; Esposito A; Dìez J; López B; Dahlöf B; Nicholls MG; Smith RD; Gilles L; Magrini F; Zanchetti A
    Circulation; 2004 Aug; 110(5):552-7. PubMed ID: 15277331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Bursztyn M
    Lancet; 2002 Jun; 359(9324):2201; author reply 2203-4. PubMed ID: 12091006
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 33. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hjelmesaeth J; Carlsson PO
    Lancet; 2002 Jun; 359(9324):2201-2; author reply 2203-4. PubMed ID: 12091007
    [No Abstract]   [Full Text] [Related]  

  • 34. Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
    Aronow WS
    Lancet; 2003 Aug; 362(9384):591-2. PubMed ID: 12944056
    [No Abstract]   [Full Text] [Related]  

  • 35. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
    Greve AM; Olsen MH; Bella JN; Lønnebakken MT; Gerdts E; Okin PM; Palmieri V; Boman K; Nieminen MS; Omvik P; Dahlöf B; Devereux RB; Wachtell K
    Am J Hypertens; 2012 Sep; 25(9):1017-23. PubMed ID: 22695506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diuretics in the LIFE study.
    Kato J; Eto T
    Lancet; 2004 Jul 31-Aug 6; 364(9432):413; author reply 413-4. PubMed ID: 15288732
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Heinzl S
    Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
    [No Abstract]   [Full Text] [Related]  

  • 39. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 40. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.